Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Other Non-Current Liabilities (2021 - 2024)

Aligos Therapeutics filings provide 4 years of Other Non-Current Liabilities readings, the most recent being $72.4 million for Q4 2024.

  • On a quarterly basis, Other Non-Current Liabilities rose 162.24% to $72.4 million in Q4 2024 year-over-year; TTM through Dec 2024 was $72.4 million, a 162.24% increase, with the full-year FY2024 number at $72.4 million, up 162.24% from a year prior.
  • Other Non-Current Liabilities hit $72.4 million in Q4 2024 for Aligos Therapeutics, up from $11.6 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $72.4 million in Q4 2024 to a low of $133000.0 in Q4 2021.
  • Median Other Non-Current Liabilities over the past 4 years was $267000.0 (2021), compared with a mean of $13.9 million.
  • Biggest five-year swings in Other Non-Current Liabilities: tumbled 50.19% in 2022 and later soared 162.24% in 2024.
  • Aligos Therapeutics' Other Non-Current Liabilities stood at $133000.0 in 2021, then changed by 0.0% to $133000.0 in 2022, then soared by 20648.87% to $27.6 million in 2023, then skyrocketed by 162.24% to $72.4 million in 2024.
  • The last three reported values for Other Non-Current Liabilities were $72.4 million (Q4 2024), $11.6 million (Q3 2024), and $11.5 million (Q2 2024) per Business Quant data.